Skip to main content

Yumanity Therapeutics, Inc. (YMTX)

NASDAQ: YMTX · IEX Real-Time Price · USD
9.24 0.13 (1.43%)
Oct 22, 2021 4:00 PM EDT - Market closed
Market Cap95.02M
Revenue (ttm)12.54M
Net Income (ttm)-51.16M
Shares Out10.20M
EPS (ttm)-9.76
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume202,092
Open9.17
Previous Close9.11
Day's Range8.56 - 9.31
52-Week Range0.94 - 23.47
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 11, 2021

About YMTX

Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. It focuses on discovering disease-modifying therapies to treat Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, frontotemporal lobar degeneration, and Alzheimer's diseases. Its lead program is YTX-7739, a novel small molecule for the treatment of Parkinson's disease and related disorders of a-synuclein that...

IndustryBiotechnology
IPO DateFeb 11, 2016
CEOMeenu Chhabra
Employees44
Stock ExchangeNASDAQ
Ticker SymbolYMTX
Full Company Profile

Financial Performance

Financial Statements

News

Yumanity Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying thera...

1 week ago - GlobeNewsWire

Yumanity Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying ther...

1 month ago - GlobeNewsWire

Yumanity Therapeutics Reports Second Quarter 2021 Financial Results and Recent Corporate Developments

YTX-7739 shown to inhibit its novel target in healthy volunteers at levels consistent with improved motor function in an animal model of Parkinson's disease

2 months ago - GlobeNewsWire

Yumanity Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Developments

Demonstrated lead program YMTX-7739 inhibits novel target in healthy volunteers at levels consistent with improved motor function in an animal model of Parkinson's disease

5 months ago - GlobeNewsWire

Yumanity Therapeutics to Present at the 2021 RBC Capital Markets Global Healthcare Conference

BOSTON, May 12, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therap...

5 months ago - GlobeNewsWire

Yumanity Therapeutics to Present at the 2021 B. Riley Securities' Neuroscience Conference

BOSTON, April 28, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying ther...

5 months ago - GlobeNewsWire

Yumanity Therapeutics' YTX-7739 Achieved Target Engagement at Doses That Were Generally Well Tolerated in a Phase 1a ...

YTX-7739 is Yumanity's lead product candidate in clinical development for the treatment of Parkinson's disease YTX-7739 is Yumanity's lead product candidate in clinical development for the treatment of ...

6 months ago - GlobeNewsWire

Yumanity Therapeutics Appoints Neuroscience Drug Development Veteran, Ajay Verma, M.D., Ph.D., Executive Vice Preside...

BOSTON, April 13, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a biopharmaceutical company focused on the development of innovative, disease-modifying therapies for neurodegenerative d...

6 months ago - GlobeNewsWire

Yumanity Therapeutics' Glioblastoma Candidate Shows Efficacy In Animal Studies

Yumanity Therapeutics (NASDAQ: YMTX) has announced results from preclinical studies of YTX-7739 in glioblastoma multiforme (GBM). Researchers at the Massachusetts General Hospital conducted the study.

6 months ago - Benzinga

Yumanity Therapeutics Announces Study Demonstrating In Vivo Efficacy of YTX-7739 in a Glioblastoma Multiforme (GBM) M...

YTX-7739 demonstrates efficacy, including increased median overall survival, both as a single agent and in combination with temozolomide, the standard-of-care for GBM

6 months ago - GlobeNewsWire

Yumanity Therapeutics Reports Full Year 2020 Financial Results and Recent Corporate Developments

Closed $33.6 million PIPE in conjunction with the completion of reverse merger with Proteostasis Therapeutics; commenced trading on the Nasdaq Capital Market under the ticker symbol “YMTX”

6 months ago - GlobeNewsWire

Yumanity Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference

BOSTON, March 02, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying ther...

7 months ago - GlobeNewsWire

Yumanity Therapeutics Sees Lead Candidate Interim Data From Early-Stage Parkinson's Study By Mid-2021

Yumanity Therapeutics Inc (NASDAQ: YMTX) reported results from the Phase 1 single ascending dose study in 40-healthy volunteers, evaluating its lead candidate, YTX-7739, an SCD inhibitor, for the treatm...

8 months ago - Benzinga

Yumanity Therapeutics Provides Update on Its Lead Parkinson's Disease Clinical Program, YTX-7739

Results reported of the single ascending dose study in healthy volunteers

8 months ago - GlobeNewsWire

Yumanity Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference

BOSTON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying thera...

9 months ago - GlobeNewsWire

Yumanity Therapeutics Completes Reverse Merger with Proteostasis Therapeutics

Shares of Yumanity to commence trading on Nasdaq under new ticker symbol “YMTX” on December 23, 2020

9 months ago - GlobeNewsWire